---
search:
  boost: 3
---

# Anti-Migraine Agents, Prophylaxis

This is a subcategory of Central Nervous System (CNS) Agents.

## Formulary

### Preferred

| Preferred                                                | Generic Name                                             |         Quantity          |        Time (Days)        |
|:---------------------------------------------------------|:---------------------------------------------------------|:-------------------------:|:-------------------------:|
| Aimovig <sup>QL ST</sup>                                 | Erenumab Subcutaneous Inj (all strengths & formulations) | Determined pursuant to PA | Determined pursuant to PA |
| Ajovy <sup>QL ST</sup>                                   | Fremanezumab Subcutaneous Inj 225 MG / 1.5 ML            | Determined pursuant to PA | Determined pursuant to PA |
| Cardiovascular Agents: Beta-Blockers                     |                                                          |                           |                           |
| CNS Agents: Anticonvulsants                              |                                                          |                           |                           |
| CNS Agents: Serotonin-Norepinephrine Reuptake Inhibitors |                                                          |                           |                           |
| CNS Agents: Tricyclic Antidepressants                    |                                                          |                           |                           |

### Non-Preferred

| Non-Preferred            | Generic Name                                                 |         Quantity          |        Time (Days)        |
|:-------------------------|:-------------------------------------------------------------|:-------------------------:|:-------------------------:|
| Emgality <sup>QL</sup>   | Galcanezumab Subcutaneous Inj (all strengths & formulations) | Determined pursuant to PA | Determined pursuant to PA |
| Nurtec ODT <sup>QL</sup> | Rimegepant ODT (all strengths)                               | Determined pursuant to PA | Determined pursuant to PA |
| Qulipta <sup>QL</sup>    | Atogepant Tab (all strengths)                                | Determined pursuant to PA | Determined pursuant to PA |

## Authorizations

**Length of Authorizations**: Initial: 180 days; Subsequent: 365 days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Step Therapy

Step Therapy Approval Criteria

- Must have had an inadequate clinical response of at least ^^30 days^^ with at least ^^three preferred^^ controller migraine drugs
- Must include objective documentation of severity, frequency, type of migraine, and number of headache days per month (preferably a headache diary)

### Erenumab (Aimovig)

Erenumab (Aimovig) Criteria

- Must have had an inadequate clinical response of at least ^^60 days^^ with the 70mg dose to request a dose increase 

### Fremanezumab (Ajovy)

Fremanezumab (Ajovy) Criteria

- Must have demonstrated efficacy for at least ^^90 days^^ before quarterly administration will be authorized

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least ^^30 days^^ with at least ^^three preferred^^ controller migraine drugs **AND** ^^one step therapy^^ drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Additional Information

- Controller migraine drug classes include beta-blockers, anticonvulsants, tricyclic antidepressants, or serotonin-norepinephrine reuptake inhibitors 

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment (preferably a headache diary or other objective documentation of severity, frequency, and number of headaches per month).

**QL** - Nurtec ODT: 18 doses per 30 days for ^^prophylactic^^ treatment </br>
**QL** - Aimovig, Ajovy: 1 dose per 30 days </br>
**QL** - Emgality: 2 doses per 30 days (for initial loading dose only), then 1 does per 30 days thereafter

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7BCD777F63-7F18-4713-8D6A-B043BEE631F5%7D&file=Denial%20Language%20Updated%2009112023.docx&action=embedview&mobileredirect=true&wdStartOn=24&cid=f4472ece-6d4f-4694-b0c5-c150a2f53fea){:target="_blank" rel="noopener"}

[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701+UPDL+Criteria+_v1_FINAL.approved.pdf#page=28){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701_UPDL_FINAL_ODM.approved.v2.pdf#page=14){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
